scholarly journals Rethinking methods used to evaluate effectiveness of therapeutics for COVID-19 and other viral respiratory illnesses

2022 ◽  
Author(s):  
Jean-François Rossignol
2010 ◽  
Vol 21 (6) ◽  
pp. 990-996 ◽  
Author(s):  
Michael E. Possin ◽  
Stephanie Morgan ◽  
Douglas F. DaSilva ◽  
Christopher Tisler ◽  
Tressa E. Pappas ◽  
...  

Author(s):  
A. Subramanian ◽  
M.K. McGraw ◽  
J. Carlin ◽  
K. Zolfaghari ◽  
J. Ettlinger ◽  
...  

Nutrients ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 3163
Author(s):  
Liisa Lehtoranta ◽  
Sinikka Latvala ◽  
Markus J. Lehtinen

Viral respiratory tract infection (RTI) is the most frequent cause of infectious illnesses including the common cold. Pharmacological solutions for treating or preventing viral RTIs are so far limited and thus several self-care products are available in the market. Some dietary supplements such as probiotics have been shown to modulate immune system function and their role in reducing the risk and the course of RTIs has been investigated extensively within the past decade. However, the mechanism of action and the efficacy of probiotics against viral RTIs remains unclear. We searched PubMed, Google Scholar, and Web of Knowledge for pre-clinical and clinical studies investigating the effect of probiotics on respiratory virus infections, immune response, and the course of upper and lower respiratory tract illness. The literature summarized in this narrative review points out that specific probiotic strains seem effective in pre-clinical models, through stimulating the immune system and inhibiting viral replication. Clinical studies indicate variable efficacy on upper respiratory illnesses and lack proof of diagnosed viral infections. However, meta-analyses of clinical studies indicate that probiotics could be beneficial in upper respiratory illnesses without specific etiology. Further studies aiming at discovering the mechanisms of action of probiotics and clinical efficacy are warranted.


Author(s):  
Patrick D. Shaw Stewart ◽  
Julia Bach

This review seeks to explain four features of viral respiratory illnesses that have perplexed generations of virologists: (1) the seasonal timing of respiratory illness; (2) the common viruses causing respiratory illness worldwide, including year-round disease in the Tropics; (3) the rapid response of outbreaks to weather, specifically temperature; (4) the rapid arrival and termination of epidemics caused by influenza and other viruses. The inadequacy of the popular explanations of seasonality is discussed, and a simple hypothesis is proposed, called Temperature Dependent Viral Tropism (TDVT), that is compatible with the above features of respiratory illness. TDVT notes that viruses can transmit themselves more effectively if they moderate their pathogenicity (thereby maintaining host mobility) and suggests that endemic respiratory viruses accomplish this by developing thermal sensitivity within a range that supports organ-specific viral tropism within the human body, whereby they replicate most rapidly at temperatures below body temperature. This allows them to confine themselves to the upper respiratory tract and to avoid infecting the lungs, heart, gut etc. Biochemical and tissue-culture studies show that “wild” respiratory viruses show such natural thermal sensitivity. The typical early autumn surge of colds and the existence of respiratory illness in the Tropics year-round at intermediate levels are explained by the tendency for strains to adapt their thermal sensitivity to their local climate and season. The TDVT hypothesis has important practical implications for preventing and treating respiratory illness including Covid-19. TVDT is testable with many options for experiments to increase our understanding of viral seasonality and pathogenicity.


PEDIATRICS ◽  
1968 ◽  
Vol 42 (1) ◽  
pp. 208-208
Author(s):  
I. J. Wolf

We have been having an epidemic of respiratory infections in this area for the past 2 months, considered to be viral in character. In the past 25 days I have seen 9 girls of the following ages who developed morbilliform rashes at the terminal stages of their respiratory illnesses: 7 months, 4 years (2), 7 years, 8 years, 9 years, 11 years, 12 years, and 18 years. At the time the rashes appeared the patients had no fever and were not acutely ill.


Sign in / Sign up

Export Citation Format

Share Document